According to market estimates, the U.S. market for Mycophenolate Mofetil is approximately US$ 30 million. The approval positions the company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets.

Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.

The company’s consolidated net profit declined 36.75% to Rs 88.79 crore on 24.15% drop in revenue frm operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25